Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trialÉtienne Garin, Lambros Tselikas, Boris Guiu et al.|The Lancet. Gastroenterology & hepatology|2020Cited by 602
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean François Seitz, Pascal Hammel et al.|JAMA Oncology|2022Cited by 322
Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspManuel Rodrigues, Shufang Renault, Toulsie Ramtohul et al.|Nature Communications|2024Cited by 30
Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response MechanismBaptiste Louveau, Célèste Lebbé, Matthieu Resche‐Rigon et al.|Clinical Cancer Research|2021Cited by 19
Phase I-II open label multicenter study of PD0332991 in <i>BRAF<sup>V600mut</sup></i> metastatic melanoma patients harboring <i>CDKN2A</i> loss and RB1 expression and treated with vemurafenib.Baptiste Louveau, Célèste Lebbé, Matthieu Resche‐Rigon et al.|Journal of Clinical Oncology|2019Cited by 5